A consortium led by GL Capital Group ("GL Capital”), a leading healthcare-focused private equity firm, has made a significant minority investment in Sangon Biotech (Shanghai) Co., Ltd ("Sangon Biotech" or "Sangon" or "the Company"). Founded in 1995, Sangon Biotech is a leading supplier of life science research products and services in China, specialising in DNA synthesis, genetic engineering services, life science research reagents and consumables, and protein and antibody related products. GL Capital will work with the current CEO, Tracey Wang, and the Sangon Biotech team to continue to build on the growth of the Company's existing product and service offerings.

Sangon Biotech has strong competitive strength in the DNA synthesis market in China and offers one of the most comprehensive product lines in the life science tools industry. The company aims to become a 'one-stop-shop' provider for both research and industrial customers. Sangon's extensive sales network covers almost all universities, research institutions and over 13,000 pharmaceutical and biotech companies in china. The company has also established seven direct sales outlets globally, covering most regions in Asia, North America, South America, and Europe.

This transaction significantly expands GL Capital's investment footprint in the life science tools industry, which offers attractive structural growth opportunities in China and globally, driven by the development of precision medicine and the rising R&D spending in life science research.

"We have been following the life sciences industry for a long time and believe it is one of the most attractive growth markets." states Jefrey Li, Founding Partiner at GL Capital. "Sangon Biotech, as a leading player in China, has strong brand recognition by  research and industrial customers. We will leverage our value creation capabilities to help Sangon maintain fast growth, further expand the customer base and execute its vision to become the industry leader in China."

About GL Capital